Team:Wageningen UR/Modeling

From 2012.igem.org

(Difference between revisions)
(→Introduction)
(→Modeling)
 
(117 intermediate revisions not shown)
Line 1: Line 1:
{{Template:WUR}}
{{Template:WUR}}
 +
<html>
 +
<script>
 +
document.getElementById("header_slider").style.backgroundImage = "url(https://static.igem.org/mediawiki/2012/d/d2/HeaderModeling.jpg)";
 +
</script>
 +
</html>
-
== Modelling ==
+
= Modeling =
-
=== Introduction ===
+
Formation of modified Virus-Like Particles is key to the success of our project. Therefore we first [[Team:Wageningen_UR/InSilico|predict the structure of the subunits]] after which we use a [[Team:Wageningen_UR/FormationModel|model describing the formation of the whole VLPs]].
-
In our [[Team:Wageningen_UR/Project|project]] there are multiple aspects that we can model. Starting at the modelling of the formation of VLPs under different conditions, continuing at a dispersion model for when VLPs are injected into a human body and ending at marcro-models for degredation of VLPs in the environment.
+
Finally, we wanted to know the applicability of our device. Therefore, we used a human body model which is based on the model made by the [[Team:Slovenia/ModelingPK|Slovenia 2012 iGEM team]]. We extensively modifyed this model to make it applicable for VLPs, their affinity with diseased tissue, the speed of excretion and degradation and finally, the drug delivery at the targeted tissue.
-
We chose to model both VLP formation and VLP dispersion in the human body.
+
-
=== VLP Formation ===
+
*[https://2012.igem.org/Team:Wageningen_UR/HumanBody Human Body Model]
-
 
+
*[https://2012.igem.org/Team:Wageningen_UR/InSilico Tertiary Structure Modeling]
-
 
+
*[https://2012.igem.org/Team:Wageningen_UR/FormationModel VLP Assembly Model]
-
 
+
-
=== ... ===
+

Latest revision as of 19:12, 26 October 2012

Modeling

Formation of modified Virus-Like Particles is key to the success of our project. Therefore we first predict the structure of the subunits after which we use a model describing the formation of the whole VLPs.

Finally, we wanted to know the applicability of our device. Therefore, we used a human body model which is based on the model made by the Slovenia 2012 iGEM team. We extensively modifyed this model to make it applicable for VLPs, their affinity with diseased tissue, the speed of excretion and degradation and finally, the drug delivery at the targeted tissue.

Retrieved from "http://2012.igem.org/Team:Wageningen_UR/Modeling"